Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Beads Complicated by Interstitial Pneumonitis

ABSTRACT

Transarterial chemoembolization has proven benefit in the treatment of unresectable hepatocellular carcinoma (HCC). Commonly reported symptoms following chemoembolization with or without drug-eluting beads include abdominal pain, nausea, and low-grade fever, which typically limited resolve within a few days. A recent study comparing traditional chemoembolization versus chemoembolization with drug-eluting beads demonstrated similar survival between the two techniques, but improved tolerability when the drug-eluting beads were used. This case report describes a patient with unresectable HCC undergoing chemoembolization with drug-eluting beads. The postprocedure course was complicated by interstitial pneumonitis secondary to shunting of the drug-eluting beads containing doxorubicin to both lungs via tumor vasculature. This case highlights the relationship between the number and size of the tumors to be treated, arteriovenous shunting within the liver/tumors, and the size of the embolization particles.

KEYWORDS

Hepatocellular cancer - transarterial chemoembolization

REFERENCES

• 1 Bosch F X, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 (5, Suppl 1) S5-S16
• 2 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.  N Engl J Med. 1995;  332 (19) 1256-1261
• 3 Lo C M, Ngan H, Tso W K et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35 (5) 1164-1171
• 4 Llovet J M, Real M I, Montaña X Barcelona Liver Cancer Group et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  359 (9319) 1734-1739
• 5 Lammer J, Malagari K, Vogl T PRECISION V Investigators et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.  Cardiovasc Intervent Radiol. 2010;  33 (1) 41-52
• 6 Dhanasekaran R, Kooby D A, Staley C A, Kauh J S, Khanna V, Kim H S. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).  J Surg Oncol. 2010;  101 (6) 476-480
• 7 Wu G C, Perng W C, Chen C W, Chian C F, Peng C K, Su W L. Acute respiratory distress syndrome after transcatheter arterial chemoembolization of hepatocellular carcinomas.  Am J Med Sci. 2009;  338 (5) 357-360
• 8 Kwok P C, Lam T W, Lam C L, Lai A K, Lo H Y, Chan S C. Rare pulmonary complications after transarterial chemoembolisation for hepatocellular carcinoma: two case reports.  Hong Kong Med J. 2003;  9 (6) 457-460
• 9 Chung J W, Park J H, Im J G, Han J K, Han M C. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma.  Radiology. 1993;  187 (3) 689-693
• 10 Matsumoto K, Nojiri J, Takase Y et al.. Cerebral lipiodol embolism: a complication of transcatheter arterial chemoembolization for hepatocellular carcinoma.  Cardiovasc Intervent Radiol. 2007;  30 (3) 512-514
• 11 Choi C S, Kim K H, Seo G S et al.. Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma.  World J Gastroenterol. 2008;  14 (30) 4834-4837
• 12 Leung T W, Lau W Y, Ho S K et al.. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors.  Int J Radiat Oncol Biol Phys. 1995;  33 (4) 919-924
• 13 Salem R, Parikh P, Atassi B et al.. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution.  Am J Clin Oncol. 2008;  31 (5) 431-438